TARGET Trial

INTERVENTION: Participants are randomly allocated to one of two groups. Intervention group: Participants will undergo a PET‐CT scan prior to their CT guided biopsy. The PET‐CT images and reports will be made available to the biopsy performing radiologists, ahead of the scheduled biopsy date. Control group: Participants will undergo a CT guided biopsy alone. CONDITION: Topic: Cancer; Subtopic: Lung Cancer; Disease: Lung (non‐small cell) ; Cancer ; Pleural malignancy PRIMARY OUTCOME: Diagnostic accuracy of the PET‐CT scan in the detection of pleural malignancy is determined using biposy results. SECONDARY OUTCOME: 1. Diagnostic delay; 2. Number of hospital attendances; 3. Number of invasive pleural procedures; 4. Survival; 5. Costs associated with health related resource use; 6. Mesothelin levels INCLUSION CRITERIA: Current participant inclusion criteria as of 17/11/2017: Participants may be eligible for the study if ALL the following apply: 1. Pleural thickening on CT suspicious for pleural malignancy 2. Have had any form of pleural biopsy in the last 12 months (either by thoracoscopy or under radiological guidance) which was non‐diagnostic for cancer 3. Lung Cancer/mesothelioma MDT decision to perform further CT‐guided biopsy to pursue a diagnosis Previous participant INCLUSION CRITERIA: 1. Aged 18 years or over 2. Pleural thickening on CT suspicious for malignancy 3. Have had any for of pleural biopsy in the last 6 months (either by thoracoscopy or under radiological guidance) which was non­diagnostic for cancer 4. Lung Cancer/Mesothelioma Multidisciplinary team (MDT) decision to perform further CT guided biopsy to pursue a diagnosis